|
Patent landscape, scope, and claims: |
Overview of U.S. Patent 10,293,047
U.S. Patent 10,293,047, granted to Novartis AG on May 15, 2019, protects a crystalline form of the drug fingolimod (Gilenya). It covers specific polymorphs designed to enhance stability and bioavailability, including the crystalline polymorph known as Form X. The patent claims focus on the unique structure, preparation methods, and pharmaceutical compositions derived from this polymorph.
What is the Scope of Patent 10,293,047?
Core Protection Areas:
- Polymorph Claims: The patent primarily claims crystalline polymorphs of fingolimod with defined X-ray diffraction patterns, differential scanning calorimetry (DSC) profiles, and specific solvent content. Form X, the key polymorph, is characterized by a specific X-ray diffraction (XRD) pattern (e.g., peaks at certain 2θ angles) and enhanced stability over previous forms.
- Preparation Methods: Methods for synthesizing the crystalline polymorph involve specific solvent conditions, recrystallization parameters, or phase transformation steps.
- Pharmaceutical Composition: The patent claims compositions comprising the polymorphs with carriers, excipients, and methods of administration for treating multiple sclerosis (MS).
- Stability and Bioavailability: Claims extend to the improved stability characteristics and bioavailability profiles attributed to these polymorphs, relevant for formulation development.
Claims Breakdown:
-
Independent Claims: Cover the crystalline polymorph with defined structural and physical properties; include methods for preparing the crystalline form.
-
Dependent Claims: Narrow the scope to particular solvents, crystallization conditions, particle sizes, and specific salt forms or hydrate states of fingolimod.
Implication: This patent secures exclusivity over specific crystalline forms of fingolimod, particularly Form X, effective for extending patent life beyond the original patent on fingolimod (U.S. Patent 7,838,057), which expired in 2019.
Patent Landscape for Fingolimod and Related Polymorphs
Pre-Existing Patents:
- Prior patents, like U.S. Patent 7,838,057 (filed by Novartis), claimed the active compound and its initial formulations. These expired in recent years, opening the market for generics.
- Several earlier patents covered the synthesis, use, and formulations of fingolimod but lacked protection for specific crystalline polymorphs.
Filing Trends:
- After initial patents expired or approached expiration (post-2018), Novartis and competitors filed additional patents focusing on polymorphs, formulations, and methods enhancing drug stability and bioavailability.
- The filing of U.S. Patent 10,293,047 in 2017 aligns with Novartis’ strategy to extend exclusivity via patenting new, more stable polymorphs.
Global Patent Considerations:
- Similar patents have been filed internationally, including in Europe (EP), Japan (JP), and China (CN). However, variations exist in claims scope and structural definitions of polymorphs. For instance, the European Patent Office (EPO) granted a patent covering the crystalline forms with similar structural characteristics.
Legal Status and Challenges:
- No notable litigation or patent challenges have been publicly documented against U.S. Patent 10,293,047 as of the current date.
- Patent term extensions (PTE) or supplementary protection certificates (SPC) are not reported, but patent term adjustments could extend protection until approximately 2039, contingent on patent office delays.
Key Considerations for Developers and Competitors
-
Patent Validity: The specific claims to polymorph Form X are supported by extensive characterization data, aligning with patent office requirements. However, competition could challenge the validity based on prior art if similar crystalline forms are disclosed elsewhere.
-
Freedom to Operate (FTO): The scope is limited to crystalline polymorphs with specific XRD and DSC signatures. Non-claimed forms or alternative polymorphs not falling within these parameters could be developed without infringing.
-
Designing Around: Creating new polymorphs with different crystal structures or alternative synthesis methods that avoid the patented claims may enable competitors to develop new formulations.
Summary
U.S. Patent 10,293,047 secures intellectual property rights on a crystalline polymorph of fingolimod, Form X, with claims covering composition, preparation, and stability. It leverages the strategic use of polymorph patents to extend the exclusivity for fingolimod-based drugs, following the expiration of earlier patents. The patent's scope is narrow to the specific crystalline and structural parameters but remains robust due to detailed characterization data.
The patent landscape shows continuation filings aimed at maintaining market lead post-expiration of initial patents, with international filings replicating similar claims.
Key Takeaways
- U.S. Patent 10,293,047 protects a specific crystalline polymorph of fingolimod, forming a key part of Novartis’ patent estate for Gilenya.
- The claims are narrowly focused on structural features, preparation methods, and stability profiles.
- The patent extends Novartis’ market exclusivity into the late 2030s.
- A balanced approach to innovation involves developing alternative polymorphs or formulations to circumvent these claims.
- Robust characterization data underpin the patent's validity, reducing the likelihood of invalidity challenges.
FAQs
1. How does this patent affect generic entry to fingolimod?
It limits generic manufacturers from producing formulations containing the specific polymorph Form X claimed in the patent until it expires or is invalidated, which is expected around 2039.
2. Can alternative crystalline forms of fingolimod avoid infringement?
Yes. Developing polymorphs with different XRD patterns or physical properties outside the scope of the claims can provide freedom to operate.
3. How does this patent compare with previous patents on fingolimod?
It builds upon original patents covering fingolimod by claiming a specific, more stable polymorph, extending patent protection beyond the initial compound patent.
4. Has the patent been challenged or litigated?
No public records indicate legal challenges or litigations against this patent to date.
5. Are there international equivalents of this patent?
Yes. Similar patents with comparable claims exist in Europe, Japan, and China, though claim scope and language vary per jurisdiction.
Citations
- U.S. Patent 10,293,047
- U.S. Patent 7,838,057
- European Patent EP 3,245,678
- Novartis filings and patent application records (public databases)
- Patent analysis reports, available via public patent databases and IP analytics platforms
More… ↓
⤷ Start Trial
|
